Juan Jesús
Cruz Hernández
University of Paris-Saclay
Gif-sur-Yvette, FranciaPublicacións en colaboración con investigadores/as de University of Paris-Saclay (2)
2021
-
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 4, pp. 463-475
-
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
The Lancet Oncology, Vol. 22, Núm. 5, pp. 727-736